Table 2.
CTC quantity partitioned for each technique of CTC detection and outlined for each follow-up timepoint with association of the impact of adjuvant chemotherapy on the CTC quantity over the study period.
| t0 | p | t1 | p | t2 | p | t3 | p | t4 | p | t5 | p | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NyOne | ||||||||||||
| CTC positive patients: fraction (%) | 16/44 (36.4) | 12/22 (54.5) | 12/22 (54.5) | 9/20 (45.0) | 7/12 (58.3) | 6/8 (75.0) | ||||||
| CTC count per patient: mean (SD) | 0.89 (1.57) | 1.18 (1.33) | 1.50 (2.61) | 1.00 (1.69) | 1.33 (1.67) | 4.25 (10.01) | ||||||
| CTC count according to adjuvant chemotherapy | ||||||||||||
| CTX+: mean (SD) | 1.50 (2.28) | ns | 2.60 (1.34) | ns | 2.25 (3.28) | ns | 0.86 (0.90) | ns | 0.83 (0.98) | ns | 7.75 (14.17) | 0.015 |
| CTX-: mean (SD) | 0.60 (1.04) | 0.76 (1.03) | 1.07 (2.16) | 1.08 (2.02) | 1.83 (2.14) | 0.75 (0.50) | ||||||
| CK20 RT-qPCR | ||||||||||||
| CTC positive patients: fraction (%) | 33/41 (80.5) | 19/22 (86.4) | 17/22 (77.3) | 16/20 (80.0) | 7/12 (58.3) | 8/8 (100.0) | ||||||
| CTC count per patient: mean (SD) | 3.11 (3.81) | 3.55 (6.17) | 3.08 (3.19) | 2.41 (1.62) | 1.61 (1.95) | 4.16 (5.66) | ||||||
| Patients ≥ cut-off: fraction (%) | 15/41 (36.6) | 8/22 (36.4) | 11/22 (50.0) | 10/20 (50.0) | 2/12 (16.7) | 3/8 (37.5) | ||||||
| CTC count according to adjuvant chemotherapy | ||||||||||||
| CTX+: mean (SD) | 2.43 (2.42) | ns | 2.00 (1.85) | ns | 3.21 (3.98) | ns | 1.74 (1.45) | ns | 1.21 (1.49) | ns | 1.86 (0.55) | ns |
| CTX-: mean (SD) | 3.40 (4.26) | 4.14 (7.13) | 3.00 (2.81) | 2.76 (1.64) | 2.01 (2.41) | 6.45 (7.77) |
All p values in bold are regarded as statistically significant. UICC, Union internationale contre le cancer; SD, standard deviation; CTC, Circulating tumor cells; CTX, chemotherapy; ns, not significant.